Literature DB >> 32347884

Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum.

Alexis B Lyons1, Anjelica Peacock2, Shanice A McKenzie3, Gordon Jacobsen1, Haley B Naik4, Vivian Y Shi5, Iltefat H Hamzavi1, Jennifer L Hsiao3.   

Abstract

Importance: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing potential. There is a paucity of data regarding the HS disease course during pregnancy and in the postpartum period. Objective: To explore the HS disease course during pregnancy and in the postpartum period. Design, Setting, and Participants: A retrospective cohort study was conducted on patients in the Henry Ford Health System, Detroit, Michigan-a large, academic, urban referral center. Women with a diagnosis of HS who became pregnant between January 1, 2008, and December 31, 2018, were included. International Classification of Diseases, Ninth Revision, and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, were used for identification of the diagnosis. Exposures: Pregnancy in patients with HS. Main Outcomes and Measures: Hidradenitis suppurativa disease status during pregnancy and the postpartum period.
Results: A total of 127 women with HS were included in this study and accounted for 202 pregnancies. Of the 202 pregnancies, 171 were in black women, 25 in white women, 3 in women of other race/ethnicity, and 3 had unreported data. Mean (SD) age at HS onset was 19.3 (5.6) years; at time of HS diagnosis, 24.4 (5.3) years; and at time of pregnancy, 25.9 (5.0) years. The disease worsened during pregnancy in 70 pregnancies (61.9%), did not change in 34 pregnancies (30.1%), and improved in 9 pregnancies (8.0%). Hidradenitis suppurativa exacerbated in the postpartum period after 82 of 124 pregnancies (66.1%). Dermatologists were involved in managing HS in 28 pregnancies (14.4%) and for a higher proportion of patients with more severe Hurley stage as compared with cases of mild disease (stage 3: 7 of 18 [38.9%] vs stage 1: 10 of 100 [10.0%] or stage 2: 11 of 67 [16.4%]; P = .004). In addition, HS medical treatment was administered during 77 pregnancies (38.1%), while HS procedural treatment was administered during 34 pregnancies (16.8%). A significantly higher proportion of patients whose care was managed by dermatologists vs those without dermatologist involvement received any HS medication (22 [78.6%] vs 53 [31.7%], P < .001) or any HS procedure (14 [50%] vs 19 [11.4%], P < .001) during pregnancy. Conclusions and Relevance: Despite a high rate of HS exacerbation during pregnancy and postpartum, this cohort study found that most of the patients did not receive HS-directed medical treatment or care from a dermatologist during pregnancy. Close monitoring and improved collaborative care between dermatology and obstetrics-gynecology services is warranted.

Entities:  

Mesh:

Year:  2020        PMID: 32347884      PMCID: PMC7191431          DOI: 10.1001/jamadermatol.2020.0777

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  9 in total

Review 1.  Inflammatory Mechanisms in Hidradenitis Suppurativa.

Authors:  G Kelly; Errol P Prens
Journal:  Dermatol Clin       Date:  2016-01       Impact factor: 3.478

Review 2.  Management of hidradenitis suppurativa in pregnancy.

Authors:  Powell Perng; John G Zampella; Ginette A Okoye
Journal:  J Am Acad Dermatol       Date:  2016-12-29       Impact factor: 11.527

3.  Considering the impact of pregnancy on the natural history of hidradenitis suppurativa.

Authors:  P Perng; J G Zampella; G A Okoye
Journal:  Br J Dermatol       Date:  2017-12-08       Impact factor: 9.302

4.  Menses and pregnancy affect symptoms in hidradenitis suppurativa: A cross-sectional study.

Authors:  Allard R J V Vossen; Kelsey R van Straalen; Errol P Prens; Hessel H van der Zee
Journal:  J Am Acad Dermatol       Date:  2017-01       Impact factor: 11.527

5.  The natural history of hidradenitis suppurativa.

Authors:  J M von der Werth; H C Williams
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-09       Impact factor: 6.166

6.  Postpartum period: three distinct but continuous phases.

Authors:  Mattea Romano; Alessandra Cacciatore; Rosalba Giordano; Beatrice La Rosa
Journal:  J Prenat Med       Date:  2010-04

7.  Endocrine factors in pre- and postmenopausal women with hidradenitis suppurativa.

Authors:  J H Barth; A M Layton; W J Cunliffe
Journal:  Br J Dermatol       Date:  1996-06       Impact factor: 9.302

8.  Risk factors, clinical course and long-term prognosis in hidradenitis suppurativa: a cross-sectional study.

Authors:  C B Kromann; I E Deckers; S Esmann; J Boer; E P Prens; G B E Jemec
Journal:  Br J Dermatol       Date:  2014-09-07       Impact factor: 9.302

9.  Factors Associated With Point-of-Care Treatment Decisions for Hidradenitis Suppurativa.

Authors:  Amit Garg; Justin Besen; Aaron Legler; Christina S Lam
Journal:  JAMA Dermatol       Date:  2016-05-01       Impact factor: 10.282

  9 in total
  3 in total

Review 1.  Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis.

Authors:  Justine R Seivright; Natalie M Villa; Tristan Grogan; Ram K Parvataneni; Alyssa M Thompson; Vivian Y Shi; Jennifer L Hsiao
Journal:  Dermatology       Date:  2021-08-17       Impact factor: 5.366

2.  Reproductive Potential and Outcomes in Patients with Hidradenitis Suppurativa: Clinical Profile and Therapeutic Implications.

Authors:  Trinidad Montero-Vilchez; Luis Salvador-Rodriguez; Andrea Rodriguez-Tejero; Manuel Sanchez-Diaz; Salvador Arias-Santiago; Alejandro Molina-Leyva
Journal:  Life (Basel)       Date:  2021-03-26

Review 3.  Impact of Psoriasis and Hidradenitis Suppurativa in Pregnancy, a Systematic Review.

Authors:  Maria-Angeles Ferrer-Alcala; Manuel Sánchez-Díaz; Salvador Arias-Santiago; Alejandro Molina-Leyva
Journal:  J Clin Med       Date:  2021-12-15       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.